

CORRECTION

Open Access



Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

Hanren Dai^{1,2,3}, Zhiqiang Wu¹, Hejin Jia², Chuan Tong¹, Yelei Guo¹, Dongdong Ti¹, Xiao Han¹, Yang Liu⁴, Wenying Zhang², Chunmeng Wang², Yajing Zhang², Meixia Chen², Qingming Yang², Yao Wang^{1*} and Weidong Han^{1,2*}

Correction to: J Hematol Oncol 13, 30 (2020)
<https://doi.org/10.1186/s13045-020-00856-8>

The original article [1] contained omissions in Fig. 2, Fig. 3 & Fig. 5 which were mistakenly introduced by the production team handling this article. The original article has now been corrected to reflect the correct presentation of these figures.

Author details

¹Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China. ²Department of Bio-therapeutic, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China. ³State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China. ⁴Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China.

Published online: 18 May 2020

Reference

1. Dai H, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. *J Hematol Oncol.* 2020;13:30 <https://doi.org/10.1186/s13045-020-00856-8>.

The original article can be found online at <https://doi.org/10.1186/s13045-020-00856-8>.

* Correspondence: wangyao301@163.com; hanwdrsw69@yahoo.com; hanwdrsw@sina.com

¹Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.